CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649
| Title | CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649 |
|---|---|
| Description | Communicate correlation of exploratory biomarker analyses with efficacy of N+C or N+I |
| Organism | Homo sapiens |
| Data Type | Other Type of Genomic Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA011537 |
| Release Date | 2024-07-01 |
| Submitter | lin shen (linshenpku@163.com) |
| Organization | Beijing Cancer Hospital |
| Submission Date | 2024-05-30 |
The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX006555-02 | Nivolumab+ chemotherapy or ipilimumab in gastroesophageal cancer: CheckMate 649 biomarker analyses | 1 | Other Type of Genomic Data | 2.2 MB | zip | 0 | Unavailable |